Pipeline
Eclipse reports positive phase 2 topline data on DME steroid implant
EC-104 demonstrated durability, consistent anatomical response, and a strong safety profile; company eyes pivotal program in 2027.
Research
I-C eye drops ease mild-to-moderate dry eye in early trial
Small open-label trial found that iota-carrageenan eye drops cut dry eye symptoms by more than half under adverse conditions, with strong tolerability and no safety flags.
Research
OCT biomarkers may predict DME treatment response
Disorganization of the retinal inner layers and photoreceptor integrity biomarkers most consistently tied to visual outcomes and injection response in DME.
Business
Alcon acquires Neurotech, MacTel therapy Encelto
Clocking in at $550 million, the deal expands the company’s retinal portfolio with the first and only treatment for MacTel.
Pipeline
Stuart Therapeutics submits IND amendment for corneal wound healing
Planned proof-of-concept study is the first expansion beyond DED indication for ST-100 (vezocolmitide), with a phase 2 trial to follow in H2 2027.
Pipeline
EyePoint reports variable outcomes in latest phase 3 DURAVYU wet data readout
LUCIA trial fails to meet primary goal; company to cut workforce reduction by 53% as part of a strategic prioritization to advance phase 3 DME program.
Pipeline
Innovent's Sycume meets phase 3 endpoint for inactive TED
RESTORE-3 trial demonstrates efficacy in reducing proptosis and a favorable safety profile for patients with inactive TED.
Products
Alcon's Brytly Redness Reliever Drops receive FDA approval
Company reports effects lasting up to 12 hours for the first OTC drop in the U.S. with apraclonidine—50% longer than Lumif
Products
FDA approves RYZUMVI for presbyopia
Phentolamine ophthalmic solution 0.75% now has two indications in the U.S.; commercial launch timeframe is unknown as Viatris seeks a partner.
Business
Leadership watch: Saunders exits B+L, ZEISS names Vision Care CEO, and other executive moves
Leadership changes are underway in the eyecare space—and we’ve got the latest.
Pipeline
Roche reports phase 3 data on steroid-free therapy for UME management
Company announces FDA acceptance of BLA submission as 52-week results find vamikibart demonstrated sustained improvements in vision.
Products
FDA approves Genentech's Enspryng as first at-home TED injection
Subcutaneous version of satralizumab-mwge can be administered by a patient or caregiver following training from an HCP.
Research
Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery
Latest 3-month data demonstrate clinically meaningful IOP reductions compared to cataract surgery alone.
Pipeline
FDA clears Surrozen's IND for DME therapy
First patient dosing in the DUET trial planned for later this year; study will be the first to evaluate humans treated with the bifunctional antibody.
Events
Empire Forum co-chairs preview retina's new investor-industry meeting
Rishi Singh, MD, and David Eichenbaum, MD, explain what sets the inaugural Nov. 5 event apart, from an investor panel to first-time IRD podium data.
Pipeline
Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation
Company reports a constructive meeting with the FDA over a planned trial evaluating oral tonabersat; currently eyeing a 2027 timeframe for kickoff.
Research
Glaukos reports positive 3-year, phase 3 Epioxa clinical outcomes
Long-term extension study demonstrates clinically meaningful visual outcomes and corneal stabilization with just one treatment.
Research
GLP-1 drugs increase risk for periorbital changes
GLP-1 receptor agonist use associated with higher rates of brow ptosis, dermatochalasis and corrective oculofacial procedures.
Research
SpyGlass Pharma unveils positive 12-month data on BIM-IOL System
Interim findings offer a closer look at the safety and efficacy of the bimatoprost drug pad-intraocular lens system for OAG and OHT.
Events